LMP1-Expressing B Cells for Broad Tumor Antigen Priming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy approaches are limited by their ability to target only a single or few tumor antigens, allowing antigen-negative/loss tumor variants to escape, and checkpoint blockade therapies require pre-existing tumor antigen-specific T cells, which are lacking in many patients.
Innovation Solution
Utilizing a vector encoding a polypeptide sequence at least 90% identical to SEQ ID NO: 1, such as LMP1, to enhance antigen processing and presentation, co-stimulation, and adhesion in B cells, converting them into hyperimmunogenic antigen-presenting cells that activate a diverse TCR repertoire against tumor-associated antigens and neoantigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current immunotherapy approaches target a single or few tumor antigens, then the treatment is simple and focused, but antigen-negative/loss tumor variants can escape and treatment efficacy is limited
Solution Approach 1:
The patent uses LMP1, a universal oncogenic protein expressed in multiple EBV-associated tumor types (Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma), to create a broadly applicable immunotherapy approach. The LMP1-expressing B cells serve as universal antigen-presenting cells that can activate T cells against diverse tumor-associated antigens and neoantigens across different cancer types, making the therapy versatile rather than tumor-type-specific
Solution Approach 2:
The patent employs LMP1-expressing B cells as pre-conditioned antigen-presenting cells that are prepared in advance to present multiple tumor antigens. These pre-sensitized B cells are then used to activate patient T cells, creating a primed immune response before tumor challenge. This preliminary action ensures broad T cell activation against multiple antigens simultaneously, preventing escape by antigen-negative variants
2Adaptability or versatility
If checkpoint blockade therapies are used without pre-existing tumor antigen-specific T cells, then the therapy can be applied broadly, but the treatment fails in many patients lacking such T cells
Solution Approach 1:
The patent generates LMP1-expressing B cells in advance that serve as antigen-presenting cells to prime and activate tumor antigen-specific T cells before checkpoint blockade therapy is administered. This preliminary T cell activation ensures that when checkpoint inhibitors are given, there are already activated T cells present that can be reinvigorated by the blockade therapy, rather than attempting to activate T cells de novo in patients who lack pre-existing specificity
Solution Approach 2:
The LMP1-expressing B cells serve as an intermediary between the checkpoint blockade therapy and the tumor antigens. These B cells process and present multiple tumor antigens to T cells, bridging the gap between the broad-acting checkpoint inhibitor and the specific tumor antigens, thereby enabling checkpoint blockade to be effective even when patients lack pre-existing tumor antigen-specific T cells
3Reliability
If LMP1 is expressed in B cells to enhance immunogenicity, then antigen presentation and T cell activation are improved, but the risk of oncogenic transformation increases
Solution Approach 1:
The patent extracts only the LMP1 coding sequence from the complete Epstein-Barr virus genome and expresses it separately in B cells using viral vectors or transfection methods. This extraction approach allows expression of the immunogenic LMP1 protein without introducing other EBV oncogenes (such as EBNA1, LMP2, or EBV microRNAs) that could contribute to transformation, thereby separating the beneficial immunogenic effect from the harmful oncogenic potential
Solution Approach 2:
The patent controls the expression level, duration, and cellular context of LMP1 to maximize immunogenicity while minimizing transformation risk. By using transient transfection or self-inactivating viral vectors, the LMP1 expression is limited in time and intensity. Additionally, the use of primary B cells or well-characterized B cell lines with controlled proliferation provides a safety buffer against uncontrolled transformation, effectively tuning the parameters of LMP1 expression to achieve the desired therapeutic window
Data Source
AI summary
The disclosure provides immunogenic cells expressing LMP1, and use thereof in activating T cells and treating cancer. Also provided are methods of producing the immunogenic cells.